DIA Biosimilars 2013

Hologic

Hologic completes acquisition of Gen-Probe

Thursday, August 2, 2012 02:17 PM

Hologic, a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products, has completed its acquisition of Gen-Probe, a developer of nucleic acid tests, for approximately $3.8 billion. Gen-Probe is now a wholly-owned subsidiary of Hologic.

More... »

Cenduit: Now with Patient Reminders

Biogen Idec names VP, global commercial operations

Thursday, September 29, 2011 10:58 AM

Biogen Idec has named Tony Kingsley executive vice president, global commercial operations, effective November 7th. Kingsley will oversee development and execution of Biogen Idec’s global commercial business strategies, reporting directly to chief executive officer George A. Scangos, Ph.D. Dr. Francesco Granata, who has headed global commercial operations since early 2010, is leaving to pursue other opportunities but will remain at the company through the end of February.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs